cln2, l'esperienza della dr.ssa rita faccini
Published 6 years ago • 662 plays • Length 5:41Download video MP4
Download video MP3
Similar videos
-
1:43
incidence and risk of secondary malignancy in patients with cll
-
0:43
the role of richter’s syndrome in determining the prognosis of cll patients
-
3:33
investigating the safety and efficacy of re-treating cll patients with venetoclax-based regimens
-
1:27
safety and efficacy of nx-2127 in r/r cll: a phase i study
-
2:12
complete epigenome of cll reveals important areas of dysregulation
-
0:41
reviewing key points from the phase iii murano trial in cll
-
5:37
precision medicine and mutation detection advances in cll
-
3:09
covid-19-associated perniosis and thrombotic retiform purpura, c.m. magro et al
-
7:55
clinical trials of fixed duration treatments & novel targets in cll
-
3:10
tailoring cll therapy
-
1:39
dr. wierda on role of rituximab biosimilar in evolving cll treatment paradigm
-
0:46
dr. fakhri on tumor lysis syndrome associated with venetoclax/obinutuzumab in cll
-
4:13
front-line and r/r updates in cll from eha
-
11:40
progress report i - andrea lancz
-
2:52
updated analysis of phase iii trial of idelalisib combined with bendamustine and rituximab in cll
-
2:04
results of trial of venetoclax with bendamustine/rituximab or bendamustine/obinutuzumab in cll
-
0:49
venice ii trial: health-related qol in patients with cll treated with venetoclax
-
4:26
christine ryan, md, discusses phase ii results of acalabrutinib, venetoclax, obinutuzumab in cll
-
1:25
the management of cll in italy